Radiant Innovation

Radiant Innovation EBITDA Margin

The EBITDA Margin of Radiant Innovation (3373.TWO) as of Nov 20, 2026 is -18.15 %. In the previous year, EBITDA Margin was -14.00 % — a change of 29.64% (lower).

EBITDA Margin

-18.15 %

YoY

29.64%

Last updated:

EBITDA Margin of Radiant Innovation is 2025 -18.15 % . EBITDA Margin of Radiant Innovation was 2024 -14.00 % . It decreases by 29.64% lower compared to the previous year.

The Radiant Innovation EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
1.29 TWD
Jan 1, 2019
3.85 TWD
Jan 1, 2020
36.35 TWD
Jan 1, 2021
15.17 TWD
Jan 1, 2022
-2.69 TWD
Jan 1, 2023
-18.20 TWD
Jan 1, 2024
-14.00 TWD
Jan 1, 2025
-18.15 TWD
The Radiant Innovation EBITDA Margin history
YEAREBITDA MarginYoY
-18.15 %+29.64%
-14.00 %-23.07%
-18.20 %+577.04%
-2.69 %-117.72%
15.17 %-58.26%
36.35 %+843.06%
3.85 %+199.69%
1.29 %-69.77%
4.25 %-31.42%
6.20 %-12.04%
7.05 %+80.79%
3.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Radiant Innovation Stock analysis

What does Radiant Innovation do? Radiant Innovation Inc. generates revenue through the design, manufacture, and sale of infrared technology products. The company's main products include infrared temperature measurement instruments, ear temperature guns, frontal temperature guns, and other body temperature measurement products, alongside carbon dioxide detectors, infrared thermal imagers, and blood glucose dedicated chipsets. These products are distributed domestically and internationally across Asia, the Americas, Europe, and other regions. The primary buyers are healthcare providers, medical facilities, and electronic component distributors who require precise measurement tools and specialized components for health monitoring and diagnostics. The firm's product portfolio targets healthcare and industrial segments, with infrared thermal imagers used in building inspections and carbon dioxide detectors deployed in environmental monitoring. Blood glucose dedicated chipsets are supplied to medical device manufacturers for integration into diagnostic equipment. International distribution channels focus on regions like Asia, the Americas, and Europe, where demand for health-related measurement devices remains strong. Revenue streams are driven by direct sales to medical institutions, electronic component distributors, and industrial clients. The company's product lines serve both consumer-facing health monitoring applications and specialized industrial uses, with a strong emphasis on accuracy and reliability in temperature and gas detection technologies. Radiant Innovation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Radiant Innovation stock

EBITDA Margin of Radiant Innovation is -18.15 % in 2025.

EBITDA Margin of Radiant Innovation changed from -14.00 % to -18.15 %, representing a 29.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Radiant Innovation since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Radiant Innovation with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Radiant Innovation

All Key Metrics — Radiant Innovation